Vaxcyte, Inc. PCVX
Regular-session close
After hours · Nov 20, 4:26 PM ET
- YTD
- +20.05%
- 1 year
- +16.19%
5D -5.00 (-7.82%)
- Market cap
- 8.77B
- EPS (ttm)
- -8.05
- Shares out
- 158.30M
- Forward P/E
- -8.06
- YTD return
- +20.05%
- 1-year return
- +16.19%
- 50-day average
- 62.19
- 200-day average
- 57.78
- Enterprise value
- 8.17B
- Volume
- 1.91M
- Avg volume
- 2.17M
- Open
- 57.77
- Previous close
- 58.36
- Day's range
- 55.27 – 58.48
- 52-week range
- 42.40 – 90.75
- Beta
- 1.29
- Price target
- 116.40 (+110.1%)
- Earnings date
- Feb 23, 2027
Key statistics
- Price / book
- 3.32
- Free cash flow
- -529.82M
- Total cash
- 1.29B
- Total debt
- 221.84M
- Return on equity
- -42.68%
- Short % of float
- 9.81%
Fundamental scorecard
4 of 25 checks passed on PCVX’s reported financials
4of 25 checks passed
- Value 1 of 5
- Growth 0 of 5
- Profitability 0 of 5
- Financial health 3 of 5
- Dividend 0 of 5
Statements to Sep 30, 2026.
Analyst view
- Target (low)
- 75.00
- Target (mean)
- 116.40
- Target (high)
- 163.00
- Strong buy1
- Buy9
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 23, 2027
Expected Feb 23, 2027. Consensus EPS estimate -1.92.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 23, 2027 | Dec 30, 2026 | -1.93 | — | — | — |
| Nov 4, 2026 | Sep 30, 2026 | -2.11 | -1.99 | +0.12 | +5.69% |
| Aug 5, 2026 | Jun 30, 2026 | -2.06 | -1.97 | +0.09 | +4.37% |
| May 6, 2026 | Mar 31, 2026 | -1.78 | -2.30 | -0.52 | -29.40% |
| Feb 24, 2026 | Dec 31, 2025 | -1.53 | -1.80 | -0.27 | -17.67% |
| Nov 4, 2025 | Sep 30, 2025 | -1.27 | -1.56 | -0.29 | -22.83% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Oct 12, 2026 | Cantor Fitzgerald | reit | Overweight | Overweight |
| Oct 5, 2026 | BTIG | reit | Buy | Buy |
| Oct 5, 2026 | Needham | main | Buy | Buy |
| Oct 5, 2026 | Guggenheim | main | Buy | Buy |
| Sep 28, 2026 | B of A Securities | main | Buy | Buy |
| Sep 25, 2026 | Needham | reit | Buy | Buy |
About Vaxcyte, Inc.
Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria; and VAX-XL, a third-generation pneumococcal conjugate vaccine. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- vaxcyte.com
News
Your note
Sign in to keep a note on PCVX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| COWAN ELVIA | Officer | Sale | Nov 1, 2026 | 27,860 |
| DHALIWAL HARPREET S. | Officer | Sale | Aug 4, 2026 | 76,756 |
| EYDELMAN MIKHAIL | General Counsel | Sale | Mar 4, 2025 | 41,620 |
| GUGGENHIME ANDREW | President | Sale | Aug 2, 2026 | 167,026 |
| JODAR LUIS | Officer | Stock Award(Grant) | Sep 3, 2026 | 52,632 |
| LOXAM TERI | Director | Stock Award(Grant) | Jun 14, 2026 | 12,481 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| FMR, LLC | 14.20% | 22,480,592 | 1.25B | Sep 29, 2026 |
| Janus Henderson Group Ltd. | 11.32% | 17,919,449 | 992.56M | Sep 29, 2026 |
| T. Rowe Price Investment Management, Inc. | 9.03% | 14,300,004 | 792.08M | Sep 29, 2026 |
| Blackrock Inc. | 7.69% | 12,179,969 | 674.65M | Sep 29, 2026 |
| RA Capital Management, L.P. | 7.25% | 11,474,599 | 635.58M | Sep 29, 2026 |
| Wellington Management Group, LLP | 4.89% | 7,733,961 | 428.38M | Sep 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 2.90% | 4,587,918 | 254.12M | Jun 29, 2026 |
| T. ROWE PRICE CAPITAL APPRECIATION Fd., INC.-T. Rowe Price Capital App | 2.53% | 4,007,229 | 221.96M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 2.15% | 3,411,349 | 188.95M | Sep 29, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 2.09% | 3,312,950 | 183.50M | Jun 29, 2026 |
| Fidelity Rutland Square TRT II-Strategic Advisers Fidelity U.S. Total | 2.09% | 3,305,027 | 183.07M | Sep 29, 2026 |
| JANUS INVESTMENT FUND-Janus Henderson Forty Fund | 1.69% | 2,676,774 | 148.27M | Sep 29, 2026 |
